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Morbid obesity and bariatric surgery induce anatomical, physiological and metabolic alterations that 
may alter the body’s disposition of drugs. Current literature on this topic is limited and sometimes 
inconsistent. Cytochrome P450 (CYP) is a superfamily of enzymes that metabolize around 75% of all 
marketed drugs. The purpose of this study was to evaluate the impact of body mass index and bariatric 
surgery on CYP activities. Firstly, we evaluated the in vivo activity of 4 major CYP isoenzymes (CYP2D6, 
CYP3A4, CYP2C9, and CYP1A2) in normal weight, overweight, and morbidly obese individuals. 
Secondly, we assessed the short- (1 month) and medium-term (6 month) effects of the most commonly 
employed bariatric surgery techniques (laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass) 
on the activity of these enzymes. CYP3A4 activity was lower in morbidly obese individuals, compared 
to normal-weight controls. Interestingly, bariatric surgery normalized CYP3A4 activity. In comparison 
with normal-weight controls, morbidly obese individuals had higher CYP2D6 activity, which was only 
observed in individuals with two functional alleles for this isoenzyme. Neither body mass index nor 
surgery had significant effects on CYP2C9 and CYP1A2 activities. Overall, no relevant differences in 
CYP activities were found between surgical techniques. In conclusion, further studies should evaluate 
whether the observed alterations in CYP3A4 activity will require dose adjustments for CYP3A4 
substrates especially in morbidly obese individuals before and after bariatric surgery.
The prevalence of obesity has increased dramatically over recent last decades. According to the WHO, 39% of 
adults aged 18 years and over were overweight in 2016, and 13% were obese1. In severe obesity, life expectancy is 
reduced by an estimated 5 to 20 years, particularly among younger adults2,3. Morbid obesity is often associated 
with several pathologies including type 2 diabetes, hypertension, dyslipidemia, coronary artery disease, asthma, 
obstructive sleep apnea, and osteoarthritis4. Consequently, morbidly obese patients typically require pharmaco-
logical treatment to deal with such conditions.
Both obesity5 and bariatric surgery6 induce anatomical, physiological, and metabolic alterations that may 
affect the pharmacokinetics (including absorption, distribution, metabolism, and excretion) of drugs. This is 
especially relevant in drugs with a narrow therapeutic index since the required dose could be modified to such an 
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extent that the drug becomes inactive (by being under the minimum effective concentration) or toxic (by being 
over the maximum safe one)7,8.
Currently, there is a lack of knowledge regarding how the bioavailability and metabolism of drugs are altered 
in morbid obesity and/or after bariatric surgery9, moreover, the information available is limited10 and sometimes 
inconsistent5. As a consequence, there are only a few, specific recommendations with respect to the pharmacolog-
ical dose in patients who have undergone bariatric surgery11, and dose selection guidelines are rarely reported in 
reference textbooks and product package inserts12,13.
Cytochrome P450 (CYP) is a superfamily of heme-containing enzymes which metabolize most xenobiotics, 
including around 75% of all marketed drugs14. These enzymes catalyze the majority of phase I biotransformation 
reactions (reduction, oxidation, and hydrolysis) which generally lead to more polar compounds15. CYP genes 
are highly polymorphic, and variability in CYP content and activities have a considerable impact on drug phar-
macokinetics and clinical response16. Genetic polymorphisms of CYP are of particular relevance for CYP2A6, 
CYP2C9, CYP2C19, and CYP2D6 and lead to different pharmacogenetic phenotypes (e.g. poor, intermediate, 
extensive, and ultrarapid metabolizers)15,17.
Both morbid obesity and bariatric surgery, together with the subsequent changes in weight and body composi-
tion, are key parameters that could affect CYP activities and, consequently, the metabolism of various drugs14,18–20. 
Although there are a number of reports evaluating the effect of obesity on the activity of some CYP isoenzymes 
(e.g. CYP3A4, CYP1A2, CYP2C9, CYP2C19, and CYP2D6) most of them, as previously stated, are inconsistent 
and do not allow conclusions to be drawn5. To the best of our knowledge, no study has yet evaluated in depth the 
consequences of bariatric surgery on the activity of multiple CYP isoenzymes. In a previous report, we described 
how paracetamol pharmacokinetics and caffeine metabolism were altered after bariatric surgery21. In the present 
study, we evaluated how the activity of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 varied between normal weight, 
overweight, and morbidly obese individuals. These four CYPs were chosen due to their major involvement in the 
metabolism of drugs and their known pharmacogenetic polymorphisms. Moreover, we assessed the short- (1 
month) and medium-term (6 month) impact of two bariatric surgery procedures on the activity of these CYP 
enzymes. Additionally, the previous parameters have been evaluated in the light of CYP polymorphisms.
Results
Effect of body mass index on CYP activities. We compared the values of CYP metabolic ratios 
(CYP2D6, CYP3A4, CYP2C9, and CYP1A2) among normal weight (n = 14), overweight (n = 14), and morbidly 
obese individuals (n = 24). The metabolic ratios of CYP2D6, CYP2C9, and CYP1A2 did not differ between the 
three body mass index (BMI) categories. However, CYP3A4 presented differences: morbidly obese individuals 
had a higher metabolic ratio (and thus a lower CYP3A4 activity) than normal weight ones (p = 0.022) (Table 1). 
CYP2C9 followed the same trend although the differences did not reach statistical significance. Overall, a high 
dispersion in the metabolic ratio values of all CYP isoforms was observed. This was more pronounced (up to 4 
orders of magnitude) in the case of CYP2D6, revealing the importance of CYP2D6 genetic polymorphisms and 
subsequent inter-individual variability.
Correlation analyses between CYP activities and BMI showed that CYP1A2, CYP2D6, and CYP2C9 activities 
did not correlate with BMI (Fig. 1). A negative correlation between CYP3A4 activity and BMI was, however, 
reported. This could be observed by the fact that the DX/M3OL ratio (CYP3A4-mediated substrate/product 
ratio) had a positive correlation with BMI (Pearson r = 0.44; p = 0.001), and indicated that as BMI increased, 
CYP3A4 activity decreased.
Effect of two bariatric surgery techniques on CYP activities. We compared CYP metabolic ratios in 
morbidly obese individuals before (session 1), after 4 weeks (session 2), and after 6 months (session 3) of having 
undergone two different bariatric surgery techniques: laparoscopic sleeve gastrectomy (LSG) and laparoscopic 
Roux-en-Y gastric bypass (LRYGB) (Table 2).
We did not observe any statistical difference in CYP2D6 metabolic ratios before and after each surgical tech-
nique, neither did we find any statistical difference in CYP2D6 metabolic ratios between the two procedures. We 
then combined the individuals from both interventions to assess the effect of bariatric surgery (irrespective of 
the technique employed). We observed that the CYP2D6 metabolic ratio tended to increase 6 months following 
surgery compared to basal values, although it did not reach statistical significance (p = 0.058).
Metabolic ratio Isoenzyme Normal weight Overweight Morbid obese Differences*
DXM/DX CYP2D6 0.006 (0.004–0.008) 0.006 (0.005–0.056) 0.004 (0.002–0.024) NS
DX/M3OL CYP3A4 2.256 (1.959–3.067) 2.614 (2.117–3.722) 3.377 (2.876–4.076) Normal weight < M. obese
Losartan/EXP-3174 CYP2C9 1.754 (1.303–3.017) 1.877 (1.691–2.292) 2.745 (1.458–4.125) NS
Paraxanthine/Caffeine CYP1A2 0.339 (0.277–0.463) 0.361 (0.272–0.450) 0.383 (0.261–0.575) NS
Table 1. Metabolic ratios of CYP enzymes in normal weight (n = 14), overweight (n = 14), and morbidly obese 
patients (n = 24) after a single oral administration of modified Karolinksa cocktail containing dextromethorphan 
(30 mg), losartan (25 mg), and caffeine (65 mg). Data are expressed as median (Q1, Q3). Abbreviations: CYP: 
cytochrome P450, DXM: dextromethorphan, DX: dextrorphan, EXP-3174: the active metabolite of losartan, 
NS: not significant, M3OL: morphinan-3-ol (also known as 3-hydroxymorphinan). *P < 0.05 using the log-
transformed data.
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The CYP3A4 activity augmented as a consequence of bariatric surgery (p < 0.001) as shown by the decreased 
CYP3A4 metabolic ratio over time. Whilst such effects were reported in both surgical techniques they occurred 
earlier in LSG (where statistical significance was achieved 4 weeks after surgery and maintained at 6 months) 
compared to LRYGB (where differences were observed 6 months after surgery) (Table 2 and Fig. 2).
No differences were found in CYP2C9 activity over time after any of the two studied techniques or between 
them.
In the case of CYP1A2, its activity temporarily decreased 1 month after LRYGB (p = 0.024) and recovered 6 
months later. The same trend was observed after LSG although it did not reach statistical significance (Table 2).
Influence of genotype. In order to evaluate the relevance of genotype on CYP activities, all the study partic-
ipants were genotyped for CYP2D6, CYP3A4, CYP2C9, and CYP1A2 polymorphisms, and classified into groups 
according to their predicted phenotype and/or the number of functional alleles (in the case of CYP2C9 and 
CYP2D6) (see Supplementary Table 2). We then re-evaluated the effects of BMI and bariatric surgery on CYP2D6, 
CYP2C9, and CYP1A2 activities (this was not performed for CYP3A4 as there are no relevant polymorphisms).
Effect of BMI and surgery on CYP activities considering genotype. CYP2D6 is a highly polymor-
phic gene with a great variety of allelic variants (>60). Amongst these, there are functional alleles, reduced func-
tion alleles, and non-functional alleles, which led to a wide range of activity (ranging from no metabolic activity 
to ultra-rapid activity). As explained in the first part of the manuscript, the metabolic ratios of CYP2D6 did not 
differ between the three BMI categories (Table 1). Additionally, we did not observe any statistical difference in 
CYP2D6 metabolic ratios before and after each surgical technique (Table 2). When we excluded the individuals 
that had either 0 or 1 functional alleles for CYP2D6, and we selected only those individuals that have 2 functional 
alleles for CYP2D6, this resulted in a lower sample size (n = 26) but with a fully functional CYP2D6 (which are 
the optimal conditions to study the activity of this enzyme). We observed that morbidly obese individuals car-
rying 2 functional alleles for CYP2D6 had a lower CYP2D6 metabolic ratio (i.e. higher enzymatic activity) com-
pared to normal weight ones with 2 functional alleles (p = 0.035). Bariatric surgery tended to increase the values 
of the metabolic ratio although they did not reach statistical significance (Fig. 3).
No differences were found among groups (normal weight, overweight, and morbidly obese volunteers) for 
augmented and non-augmented CYP1A2 phenotypes. In the case of the CYP2C9 metabolic ratio, no differences 
were observed among groups with reduced, normal, and augmented CYP2C9 activity, or in individuals with 2 
functional alleles for CYP2C9 (data not shown).
Figure 1. Correlation between BMI and CYP-mediated metabolic ratios at baseline. (A) Paraxanthine/
caffeine molar ratio versus BMI; (B) Dextromethorphan/dextrorphan (DXM/DX) molar ratio versus BMI; (C) 
Dextrorphan/morphinan-3-ol (DX/M3OL) molar ratio versus BMI; (D) Losartan/EXP3174 molar ratio versus 
BMI.
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Transient alterations at 1 month (session 2) which normalized at 6 months (session 3). Another 
observation of this study is the fact that the CYP activities in some genotype subgroups were transiently altered 4 
weeks after bariatric surgery and then normalized at 6 months. For instance, after excluding the two individuals 
who had a reduced CYP2C9 activity, the remaining morbidly obese individuals with a normal CYP2C9 pheno-
type who had undergone LSG presented a reduction in CYP2C9 metabolic ratio 4 weeks after surgery (p = 0.016) 
Enzyme
Session 1 (Baseline) Session 2 (1 month post-surgery) Session 3 (6 months post-surgery)
DifferencesLRYGB LSG LRYGB LSG LRYGB LSG
CYP2D6 0.003 (0.002–0.009) 0.004 (0.002–4.172) 0.005 (0.004–0.010) 0.006 (0.002–2.324) 0.005 (0.003–0.015) 0.009 (0.003–5.079) NS
CYP3A4 3.38 (3.17–3.68) 3.29 (2.78–4.59) 2.58 (2.31–3.32) 2.01 (1.62–2.53) 2.29 (2.05–2.58) 2.46 (1.91–2.74) LRYGB S1 > S3LSG S1 > S2,S3
CYP2C9 1.65 (1.24–3.55) 3.17 (1.77–4.56) 1.91 (1.13–3.50) 1.99 (1.45–3.03) 1.73 (1.28–3.33) 3.53 (1.76–3.92) NS
CYP1A2 0.40 (0.33–0.58) 0.35 (0.19–0.61) 0.23 (0.19–0.33) 0.31 (0.14–0.66) 0.39 (0.29–0.57) 0.33 (0.27–0.78) LRYGB S1 > S2 < S3
Table 2. Phenotype indices of CYP enzymes in normal weight and morbid obese patients (n = 24) before 
(session 1), at 1 month (session 2), and 6 months (session 3) following sleeve gastrectomy (n = 10) or Roux-
en-Y gastric bypass (n = 14). Data are expressed as median (Q1, Q3). Abbreviations: CYP: cytochrome P450, 
LRYGB: Laparoscopic Roux-en-Y gastric bypass, LSG: laparoscopic sleeve gastrectomy, NS: non significant.
Figure 2. CYP3A4 phenotypic ratios (A) among normal weight, overweight, and morbid obese individuals; 
(B) in morbid obese patients prior to surgery (baseline), at 4 weeks post-surgery, and at 6 months; (C) after 
laparoscopic Roux-en-Y gastric bypass; (D) after laparoscopic sleeve gastrectomy. CYP3A4 phenotypic ratios 
were assessed by the urinary dextrorphan/morphinan-3-ol molar ratio (8 hour collection) after the intake of 
30 mg of dextromethorphan. Abbreviations: BMI: body mass index, DX: dextrorphan, LRYGB: Laparoscopic 
Roux-en-Y gastric bypass, LSG: laparoscopic sleeve gastrectomy, M3OL: morphinan-3-ol (also known as 
3-hydroxymorphinan).
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which normalized at 6 months. In a similar manner, as previously stated, the morbidly obese individuals who 
had undergone LRYGB displayed a reduction in CYP1A2 metabolic ratio 4 weeks after surgery (p = 0.024) which 
normalized at 6 months (Table 2). Further comments on these results are provided in the discussion.
Discussion
In this study we report that (1) morbidly obese individuals have a lower CYP3A4 activity than normal-weight 
healthy controls; (2) the lower CYP3A4 activity found in morbid obese individuals is normalized after bariatric 
surgery; and (3) among those carrying two functional alleles for CYP2D6, morbidly obese individuals have a 
higher CYP2D6 activity than normal weight ones.
One of the major findings of this study is that CYP3A4 activity has a negative correlation with BMI. Indeed, 
CYP3A4 activity was lower in morbidly obese individuals compared to normal-weight controls. Morphinan-3-ol 
(M3OL) is the demethylated metabolite of dextrorphan. The urinary excretion of M3OL was 27% lower in mor-
bidly obese individuals compared to the normal-weight group (8.23 vs 5.97 nmol), providing additional evidence 
that CYP3A4 activity is lesser in morbid obesity. Such results allow us to confirm the previous hypothesis that 
CYP3A4 activity may be decreased in obesity19,22–24. Indeed, previous studies have reported that in aged individu-
als, CYP3A4-catalyzed N-demethylation of erythromycin decreased as body weight increased22. The clearance of 
midazolam (a CYP3A4 substrate) was observed to be higher in obese adolescents than in morbidly obese adults, 
and the authors suggested that the greater clearance could be due to a lower CYP3A4 suppression24. The reduced 
CYP3A4 activity that we found in morbidly obese individuals could be a result of obesity comorbidities, as lower 
CYP3A4 protein expression and activity have been observed in non-alcoholic fatty liver disease and diabetes25.
Another major finding of this study is that CYP3A4 activity increased and then normalized following bariatric 
surgery. Normalization was observed 6 months after both surgical techniques and was already significant 4 weeks 
after LSG. Brill et al. studied the pharmacokinetics of midazolam in morbidly obese patients before and one year 
after bariatric surgery. They reported that midazolam clearance augmented after bariatric surgery and hypothe-
sized that this could be due to a recovery in CYP3A activity19, which is compatible with our findings.
Since CYP3A4 is involved in the phase I metabolism of approximately 50% of all commercialized drugs14, the 
fact that CYP3A4 activity is decreased in morbid obesity and increased after surgery is relevant. In light of these 
results, further studies should confirm the influence of BMI on CYP3A4 activity and the potential need of dose 
adjustments of CYP3A4 substrates in order to maintain therapeutic action. Additionally, the results of this study 
indicate that special attention should be taken in patients undergoing bariatric surgery who are taking CYP3A4 
substrates with a narrow therapeutic index (e.g. cyclosporine, tacrolimus, and sirolimus) as drug exposure will 
change14.
We did not observe any differences among the three BMI groups (normal weight, overweight, and morbidly 
obese) in the activity of the other CYPs studied (CYP2D6, CYP2C9, and CYP1A2). As genetic variants of CYP 
isoforms have been identified, and their impact on the resulting CYP activity established, we genotyped all the 
study participants and classified them accordingly. We then re-evaluated the influence of BMI and bariatric sur-
gery on CYP activities taking into consideration genotype.
When genotype was considered, we found that morbidly obese individuals bearing 2 functional alleles for 
CYP2D6 had a higher CYP2D6 activity than normal-weight controls with 2 functional alleles for this enzyme. A 
more detailed analysis revealed that such an increase in CYP2D6 activity was due to the fact that morbidly obese 
individuals presented lower levels of dextromethorphan (around 50% of the amounts present in normal weight 
and overweight individuals, probably caused by a higher volume of distribution) but similar levels of dextrorphan 
(see Supplementary Fig. 1). Paulzen et al. employed a large naturalistic population sample (>2,200 individuals) 
to evaluate the levels of risperidone and its active metabolite 9-hydroxyrisperidone (whose hydroxylation is cata-
lyzed by CYP2D6) in cachectic (<20 mg/kg2), normal weight, and obese individuals. The authors reported that 
BMI correlated positively with plasma concentrations of 9-hydroxyrisperidone26, a finding that is compatible with 
our observation that obese individuals (with 2 functional alleles for CYP2D6) have a higher CYP2D6 enzymatic 
activity than normal weight ones.
Figure 3. CYP2D6 phenotypic ratios in normal weight, overweight, and morbid obese subjects with 2 
functional alleles before (baseline), at 1 month, and 6 months after bariatric surgery. CYP2D6 phenotypic 
ratios were assessed with the urinary dextromethorphan/dextrorphan molar ratio (8-hour collection). A lower 
dextromethorphan/dextrorphan molar ratio implies an increase in CYP2D6 metabolic activity, and viceversa.  
Abbreviations: DXM: dextromethorphan, DX: dextrorphan, MO: morbidly obese.
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Another observation of our work is the temporary alteration in CYP activity observed at 4 weeks and normal-
ized at 6 months in some subgroups. For instance, obese individuals with normal/intermediate CYP2C9 activity 
who had undergone an LSG had a reduction in CYP2C9 metabolic ratio 4 weeks after surgery (p = 0.016) which 
normalized at 6 months. In a similar manner, morbidly obese individuals with an augmented CYP1A2 activity 
who had undergone an LRYGB had a reduction in CYP1A2 metabolic ratio 4 weeks after surgery (p = 0.024) 
which normalized at 6 months. Such alterations are similar to our previously reported transient decrease in 
plasma concentrations of paraxanthine after bariatric surgery21. We hypothesize that these temporary alterations 
in CYP activities could be caused by the weight-loss-induced changes in hepatic function that take place after 
bariatric surgery and which preceded a significant functional recovery of the liver27.
The fact that we observed alterations in CYP3A4 and CYP2D6 activities is relevant since both enzymes 
metabolize more than half of the available marketed drugs. It is worth noting that both CYP3A4 and CYP2D6 
activities are altered in morbid obesity although they follow different patterns (the first is decreased whereas 
the second is increased). This provides additional evidence that obesity-related alterations of CYP activities are 
isoenzyme-specific23.
The present study has some limitations. For instance, we evaluated the activity of 4 CYP isoenzymes, nev-
ertheless, additional CYPs could be explored in the future (e.g. the polymorphic CYP2A6 and CYP2C19); we 
explored the effects of bariatric surgery up to 6 months but lack information regarding long-term CYP activities; 
only two bariatric surgery techniques were assessed, they are, however, the most commonly employed; all the 
morbid obese participants were women: among the 52 participants (28 controls/24 obese), there were 50 females 
and 2 males (the latter being in the control group), the results obtained, however, are not altered by the exclusion/
inclusion of these two male subjects. On the other hand, the three major strengths of our study are the prospec-
tive and repeated measure design (in which each subject acts as the corresponding control, thus minimizing the 
influence of confounding variables and inter-individual variability); the inclusion of comparative groups (normal 
weight and overweight); and the fact that we genotyped all the participants for CYP2D6, CYP3A4, CYP2C9, and 
CYP1A2 using a DNA microarray that allows an accurate allele discrimination and screens for more than 34 genes 
and 85 allelic variants including 73 SNPs, 10 small insertions/deletions, and gene deletions and duplications28.
Conclusion
In conclusion, in comparison with normal-weight controls, morbid obese individuals had a lower CYP3A4 activ-
ity, which normalized after bariatric surgery, and a higher CYP2D6 activity, which was only observed in those 
with two functional alleles for this isoenzyme. On the basis of our findings, dose adjustments might be necessary 
when treating morbidly obese patients with drugs that are substrates of CYP3A4. Clinicians should pay special 
attention when treating morbidly obese patients taking CYP3A4 substrates with a narrow therapeutic index (e.g. 
cyclosporine, tacrolimus, and sirolimus). Finally, further studies should evaluate whether the observed alterations 
in CYP3A4 activity will require dose adjustments for CYP3A4 substrates, especially following bariatric surgery.
Methods
Subjects. A prospective cohort study was conducted in 24 severely obese patients (aged 21–54 years) who met 
the 1991 bariatric surgery criteria of the National Institutes of Health29 and who were planning to undergo bari-
atric surgery at Hospital del Mar (Barcelona, Spain). Two different surgical procedures were considered: laparo-
scopic Roux-en-Y gastric bypass (LRYGB; n = 14) and laparoscopic sleeve gastrectomy (LSG; n = 10). Indications 
for the type of surgical procedure were based on clinical criteria and the consensus of the Bariatric Surgery Unit 
as previously described30,31. For comparative purposes, 14 overweight subjects (BMI 25–30 kg/m2), and 14 normal 
weight healthy control subjects (BMI < 25 kg/m2) were additionally included in the study. The socio-demographic 
baseline characteristics and basal clinical parameters of all the study participants have been described in a previ-
ous report21 and can be found in Supplementary Table 1.
Study protocol. Participants were instructed not to consume ethanol, caffeine, and xanthine-related prod-
ucts (e.g., coffee, tea, colas, chocolate) for 2 days prior to the study sessions. This time window was chosen based 
on previous studies which reported that 16 hours of caffeine abstinence may be insufficient to avoid measuring 
methylxanthines remaining in the body, and suggested extending the abstinence period to 36 hours in future 
investigation32. In our study, we expanded this time period up to 48 hours to ensure that no remaining metabolites 
could interfere with the experiment. Subjects were excluded if they were taking medication known to induce or 
inhibit CYP enzymes or had a history of hypersensitivity to the study drugs.
After overnight fasting and baseline procedures, each subject received a modified Karolinska cocktail32,33 
including 5 drugs: dextromethorphan (Romilar®, 30 mg), losartan (Cozaar®, 12.5 mg), omeprazole (Losec®, 
20 mg), caffeine (65 mg), and paracetamol (Panadol® Extra, containing 500 mg of paracetamol and 65 mg of caf-
feine). Dextromethorphan (30 mg) was self-administered the night before each session. Losartan (25 mg), par-
acetamol–caffeine (500 and 65 mg) were administered between 08:00 and 08:15, and omeprazole (20 mg) 1 hour 
later.
Blood samples (3 mL each) were taken at 0 and 4 h after oral caffeine administration. Urine was collected over-
night after dextromethorphan administration (0–8 h), and during the experimental session following losartan/
omeprazole/paracetamol/caffeine administration (0–8 h, from 08:00 until 16:00). Plasma samples were obtained 
from whole blood by centrifugation, urine samples were aliquoted, and both plasma and urine aliquots were 
stored at −20 °C until analysis.
This procedure was performed during one session in healthy volunteers (14 overweight and 14 normal weight 
control subjects) and three times in 24 morbidly obese patients: before surgery (session 1), at 4 weeks after surgery 
(session 2), and at 6 months (session 3).
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All the morbid obese subjects were informed of the surgical risks and benefits, and signed their informed con-
sent for the surgical procedure. In addition, they signed an informed consent for study participation.
Surgical techniques. The LRYGB technique involved a 150-cm antecolic Roux limb with 25-mm circular 
pouch-jejunostomy and exclusion of 50 cm of the proximal jejunum. In LSG, the longitudinal resection of the 
stomach from the angle of His to approximately 5 cm proximal to the pylorus was performed using a 35 French 
bougie inserted along the lesser curvature. All operations were performed by the same team of surgeons.
DNA extraction and genotyping. Genomic DNA was extracted from blood samples enriched with 
white cells (buffy coat) using the FlexiGeneTM DNA kit according to the manufacturer’s instructions (Qiagen, 
Spain). Allelic variants of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 were analyzed with a DNA microarray 
(PHARMAchipTM; Progenika Biopharma SA, Spain), which includes 85 variants from 34 genes that encode five cat-
egories of proteins related to drug response28. The following allelic variants were analyzed: CYP2D6 (*1, *2, *3, *4, 
*5, *6, *7, *8, *9, *10, *11, *14 A, *14B, *15, *17, *18,*19, *20, *25, *29, *31,*35, *41, *1XN, *2XN, *4XN, *10XN, 
*17XN, *35XN, *41XN), CYP3A4 (*1, *1B), CYP2C9 (*1, *2, *3, *4, *5, *6), and CYP1A2 (*1, *1 F, *7, *11)28. 
For the subsequent analysis of CYP2D6 genotype, only the alleles *1, *2, and *35 were considered to be fully 
functional as described elsewhere34.
CYP2D6, CYP3A4, CYP2C9, and CYP1A2 genotypes were obtained for all the volunteers included in the 
study and each genotype was then classified according to the number of functional alleles. A detailed description 
of the participants’ genotypes for each studied CYP isoform can be found in Supplementary Table 2.
Analytical methods. All chemicals were of the highest grade available. Dextromethorphan, dextrorphan, 
3-methoxymorphinan, morphinan-3-ol, levallorphan (used as internal standard); caffeine, paraxanthine, and 
diphylline (used as internal standard); and losartan potassium were purchased from Sigma-Aldrich Quimica SA 
(Madrid, Spain). EXP-3174 was kindly provided by Merck Research Laboratories (New Jersey, USA).
Separation and quantification of dextromethorphan and its metabolites (3-methoxymorphinan, dextrorphan 
and morphinan-3-ol) in urine were performed by HPLC coupled with a fluorescence detector adapting a previ-
ously described method35. Briefly, a 2.5 mL aliquot of urine was spiked with 20 µL of internal standard solution 
(containing 100 µg/mL of levallorphan in methanol). Enzymatic hydrolysis of glucuronides was performed by the 
addition of 1.0 mL of β-glucuronidase HP-1 solution (pH 5; 0.1 M sodium citrate), followed by overnight (16 h) 
incubation in a water bath at 37 °C. Then 1 mL of ammonia/ammonium chloride buffer (pH 9.5) was added, the 
sample was mixed, centrifuged (5 min, 3500 rpm), and submitted to a solid-phase extraction using Bond Elut 
Certify columns (Varian, Palo Alto, CA, USA). Cartridges were conditioned with 2 mL of methanol and 2 mL 
of water. Samples were then loaded and the loaded cartridges washed with 2 mL of water, 1 mL of acetic acid 
1 M, and 2 mL of methanol. Finally, elution of the retained compounds was performed with 2 mL of chloroform: 
propanol (80:20) containing 2% ammonia. After the evaporation of the solvent under a nitrogen stream (25 °C, 
10–15 psi), they were reconstituted in 100 µL of a mixture of mobile phase, ultra-centrifuged at 10,000 rpm for 
3 min, transferred to HPLC vials, and analyzed by HPLC coupled with a fluorescence detector using a previously 
described method.
Separation and quantification of plasma caffeine and paraxanthine concentrations were performed by HPLC 
coupled to an ultraviolet detector following a previously published methodology36. Briefly, a 150 µL aliquot of 
urine was spiked with 30 µL of NaOH 0.5 M, vortexed for 5 seconds and left at room temperature for 30 min. The 
mixture was acidified by adding 40 µL of HCl 0.5 M, vortexed for 5 seconds, and spiked with 30 µL of internal 
standard solution (containing 100 µg/mL of 9-methyluric acid). Then, 100 µL of a mixture containing dimethyl-
formamide/ethyl acetate (30:70) and 800 µL of acetonitrile was subsequently added. The mixture was transferred 
to a microvial, centrifuged at 10,000 g for 5 minutes, and injected into the HPLC/UV system”.
Separation and quantification of urinary losartan and its metabolite E-3171 were carried out by HPLC coupled 
to a fluorescence detector as previously described without any modifications37.
Metabolic ratios. CYP activities were estimated with previously described drug probes and validated met-
abolic ratios. For every batch analysis, a calibration curve was performed by adding known solutions of all ana-
lytes. Calibration curves with their corresponding slope (s), intercept, and coefficient of determination (r2) were 
calculated by weighting (1/x) least-squares linear regression of the peak area ratio (analyte/internal standard) 
versus the concentration of the standards. The obtained concentrations (expressed in µg/mL or ng/mL) were 
then converted into the corresponding molar concentrations (expressed in µmol/mL or nmol/mL). Finally, the 
molar ratios were calculated by dividing molar concentrations of the substrate by the product (or viceversa) as 
follows: CYP2D6 activity was estimated by the urinary (8-hour) dextromethorphan/dextrorphan molar ratio38. 
CYP3A4 activity was estimated by the urinary (8-hour) dextrorphan/morphinan-3-ol molar ratio39,40. CYP1A2 
was estimated by the plasma (4-hour) paraxanthine/caffeine (17X/137X) molar ratio41. CYP2C9 was estimated 
as the urinary (8-hour) losartan/EXP-3174 molar ratio42. Note that CYP2D6, CYP3A4, and CYP2C9 metabolic 
ratios were calculated as substrate/product and thus a lower metabolic ratio implies a higher CYP activity and 
viceversa. However, in the case of CYP1A2 we decided to use the commonly employed paraxanthine/caffeine 
(calculated as product/substrate) and thus a lower metabolic ratio implies a lower CYP activity and viceversa. In 
addition, three of the CYP activities (CYP2D6, CYP3A4, and CYP2C9) were assessed by the analysis of urinary 
samples, and one CYP activity (CYP1A2) by measuring plasma samples. This decision was taken on the basis 
of previous reports describing that plasma, serum, and saliva are considered equally effective for measuring the 
paraxanthine/caffeine concentration ratio, whereas 30 different metabolic ratios have been proposed to measure 
CYP1A2 activity in urine after the administration of caffeine43. CYP2C19 activity evaluated by omeprazole was 
not analyzed and is not presented in this study.
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Statistical analysis. Given the fact that the interest variables were metabolic ratios, we log-transformed all 
the values before performing the statistical analyses. To compare the different weight categories (normal weight, 
overweight, and morbidly obese) with respect to metabolic ratios, one-way ANOVA models were used. Statistical 
significance was set at 0.05. A detailed description of the statistical analyses can be found in the Supplementary 
Material.
Clinical trial registration. The study was approved by the local Research Ethical Committee (CEIC-Parc 
de Salut Mar, Barcelona, Spain) and Spanish Medicines Agency (EudraCT 2009-013156-72), and registered as a 
clinical trial in a public database (ClinicalTrials.gov NCT01086722).
Ethical statement. All procedures performed in the study involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
Consent statement. Informed consent was obtained from all individual participants included in the study.
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